Management of reflux esophagitis: Does the choice of proton pump inhibitor matter?

International Journal of Clinical Practice

Volumn 69, Issue 7, 2015, Pages 796-801

  Labenz, J ^a   Armstrong, D ^b   Leodolter, A ^c   Baldycheva, I ^d  

^a Diakonie Klinikum Jung Stilling   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

^c Medical Department Ev Krankenhaus   (Germany)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; ESOPHAGOSCOPY; HEALING; HUMAN; HYPOTHETICAL MANAGEMENT MODEL; MAINTENANCE THERAPY; MODEL; NUMBERS NEEDED TO TREAT; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REMISSION; SYSTEMATIC REVIEW; TREATMENT DURATION; VALIDATION PROCESS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESOPHAGITIS, PEPTIC; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; ESOMEPRAZOLE; ESOPHAGITIS, PEPTIC; FOLLOW-UP STUDIES; HUMANS; LANSOPRAZOLE; PROTON PUMP INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84933073590     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12623     Document Type: Article

References (31)

1. Armstrong D,. Systematic review: persistence and severity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 28: 841-53.
2. Isolauri J, Luostarinen M, Isolauri E, et al., Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41.
3. Wiklund I,. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004; 22: 108-14.
4. Wiklund I, Carlsson J, Vakil N,. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006; 101: 18-28.
5. Vakil N, van Zanten SV, Kahrilas P, et al., The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20; quiz 1943.
6. Katelaris P, Holloway R, Talley N, et al., Gastro-oesophageal reflux disease in adults: guidelines for clinicians. J Gastroenterol Hepatol 2002; 17: 825-33.
7. Bixquert M,. Maintenance therapy in gastro-oesophageal reflux disease. Drugs 2005; 65 (Suppl. 1): 59-66.
8. Armstrong D, Marshall JK, Chiba N, et al., Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults-update 2004. Can J Gastroenterol 2005; 19: 15-35.
9. Chiba N,. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11 (Suppl. B): 66B-73B.
10. DeVault KR, Castell DO,. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200.
11. Castell DO, Kahrilas PJ, Richter JE, et al., Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
12. Fennerty MB, Johanson JF, Hwang C, Sostek M,. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005; 21: 455-63.
13. Kahrilas PJ, Falk GW, Johnson DA, et al., Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
14. Labenz J, Armstrong D, Lauritsen K, et al., Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005; 22: 803-11.
15. Labenz J, Armstrong D, Lauritsen K, et al., A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739-46.
16. Lauritsen K, Devière J, Bigard MA, et al., Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 24; discussion 25-7.
17. Richter JE, Kahrilas PJ, Johanson J, et al., Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
18. Schmitt C, Lightdale CJ, Hwang C, Hamelin B,. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006; 51: 844-50.
19. Vakil N,. Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis. Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 21-3.
20. Devault KR, Johanson JF, Johnson DA, et al., Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006; 4: 852-9.
21. Bell NJ, Burget D, Howden CW, et al., Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
22. Katz PO, Ginsberg GG, Hoyle PE, et al., Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007; 25: 617-28.
23. Lundell LR, Dent J, Bennett JR, et al., Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
24. Orlando RC,. Pathogenesis of gastroesophageal reflux disease. Am J Med Sci 2003; 326: 274-8.
25. Miner P Jr, Katz PO, Chen Y, Sostek M,. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
26. Miner P Jr, Katz PO, Chen Y, Sostek M,. Reanalysis of intragastric pH results based on updated correction factors for Slimline and Zinetics 24 single-use pH catheters. Am J Gastroenterol 2006; 101: 404-5; author reply 405-6.
27. Röhss K, Lind T, Wilder-Smith C,. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60: 531-9.
28. Wilder-Smith C, Lind T, Lundin C, et al., Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol 2007; 42: 157-64.
29. Wilder-Smith C, Backlund A, Eckerwall G, et al., Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. Clin Drug Investig 2008; 28: 333-43.
30. Röhss K, Wilder-Smith C, Nauclér E, Jansson L,. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig 2004; 24: 1-7.
31. Carlsson R, Dent J, Watts R, et al., Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119-24.